Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 17-May-24 4:00 PM View:  | Byrnes Michael Chief Financial Officer | Effector Therapeutics, Inc. (EFTR) | 15-May-24 | Grant | 1,387 | $1.68 | $2,334.32 | 80% 1.73K to 3.12K | |
| 17-May-24 4:00 PM View: | Worland Stephen T Chief Executive Officer Director | Effector Therapeutics, Inc. (EFTR) | 15-May-24 | Grant | 1,806 | $1.68 | $3,039.50 | 5% 33.18K to 34.99K | |
| 29-Nov-23 5:07 PM View: | Sr One Capital Management, ... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 27-Nov-23 | Sale | 609,163 | $0.61 | $369,457.00 | (9%) 6.82M to 6.21M | |
| 16-Nov-23 5:26 PM View: | Byrnes Michael Chief Financial Officer | Effector Therapeutics, Inc. (EFTR) | 15-Nov-23 | Grant | 4,524 | $0.50 | $2,249.79 | 12% 38.75K to 43.27K | |
| 16-Nov-23 5:30 PM View: | Worland Stephen T Chief Executive Officer Director | Effector Therapeutics, Inc. (EFTR) | 15-Nov-23 | Grant | 5,979 | $0.50 | $2,973.36 | < 1% 823.56K to 829.54K | |
| 14-Aug-23 8:00 AM View: | Worland Stephen T Chief Executive Officer Director | Effector Therapeutics, Inc. (EFTR) | 11-Aug-23 | Option Exercise | 33,799 | $0.52 | $17,575.50 | 4% 789.76K to 823.56K | |
| 16-May-23 8:03 AM View: | Worland Stephen T Chief Executive Officer Director | Effector Therapeutics, Inc. (EFTR) | 15-May-23 | Grant | 6,401 | $0.46 | $2,938.06 | < 1% 783.36K to 789.76K | |
| 16-May-23 8:01 AM View: | Byrnes Michael Chief Financial Officer | Effector Therapeutics, Inc. (EFTR) | 15-May-23 | Grant | 4,863 | $0.46 | $2,232.12 | 14% 33.88K to 38.75K | |
| 16-Nov-22 6:27 PM View: | Worland Stephen T Chief Executive Officer Director | Effector Therapeutics, Inc. (EFTR) | 15-Nov-22 | Grant | 6,047 | $0.47 | $2,832.41 | < 1% 777.32K to 783.36K | |
| 16-Nov-22 6:30 PM View: | Byrnes Michael Chief Financial Officer | Effector Therapeutics, Inc. (EFTR) | 15-Nov-22 | Grant | 4,651 | $0.47 | $2,178.53 | 16% 29.23K to 33.88K | |
| 06-Oct-22 8:30 AM View: | Ehrlich Christopher B Director | Effector Therapeutics, Inc. (EFTR) | 04-Oct-22 | Private Purchase | 346 | $0.57 | $197.22 | < 1% 178.07K to 178.41K | |
| 27-Sep-22 8:01 AM View: | Ehrlich Christopher B Director | Effector Therapeutics, Inc. (EFTR) | 26-Sep-22 | Private Purchase | 18,867 | $0.55 | $10,376.90 | 12% 159.2K to 178.07K | |
| 03-Aug-22 5:58 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 03-Aug-22 | Sale | 59,376 | $0.80 | $47,738.30 | (1%) 4.17M to 4.11M | |
| 03-Aug-22 5:58 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 02-Aug-22 | Sale | 28,201 | $0.80 | $22,476.20 | (< 1%) 4.2M to 4.17M | |
| 03-Aug-22 5:58 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 01-Aug-22 | Sale | 26,703 | $0.79 | $20,988.60 | (< 1%) 4.22M to 4.2M | |
| 29-Jul-22 8:54 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 28-Jul-22 | Sale | 32,517 | $0.89 | $29,005.20 | (< 1%) 4.26M to 4.22M | |
| 27-Jul-22 6:20 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 27-Jul-22 | Sale | 43,665 | $0.89 | $38,949.20 | (1%) 4.3M to 4.26M | |
| 27-Jul-22 6:20 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 26-Jul-22 | Sale | 2,775 | $0.90 | $2,508.60 | (< 1%) 4.3M to 4.3M | |
| 27-Jul-22 6:20 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 25-Jul-22 | Sale | 2,279 | $0.93 | $2,121.75 | (< 1%) 4.31M to 4.3M | |
| 22-Jul-22 6:03 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 22-Jul-22 | Sale | 7,614 | $0.91 | $6,928.97 | (< 1%) 4.31M to 4.31M | |
| 22-Jul-22 6:03 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 21-Jul-22 | Sale | 2,665 | $0.96 | $2,545.16 | (< 1%) 4.32M to 4.31M | |
| 22-Jul-22 6:03 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 20-Jul-22 | Sale | 10,030 | $1.00 | $10,040.00 | (< 1%) 4.33M to 4.32M | |
| 19-Jul-22 4:54 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 19-Jul-22 | Sale | 2,754 | $1.00 | $2,754.00 | (< 1%) 4.33M to 4.33M | |
| 19-Jul-22 4:54 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 18-Jul-22 | Sale | 20,987 | $1.08 | $22,666.60 | (< 1%) 4.35M to 4.33M | |
| 19-Jul-22 4:54 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 15-Jul-22 | Sale | 45,900 | $1.11 | $50,857.20 | (1%) 4.39M to 4.35M | |
| 27-Jun-22 6:00 AM View: | Gallagher Brian M. Jr. Director | Effector Therapeutics, Inc. (EFTR) | 23-Jun-22 | Private Purchase | 30,000 | $1.59 | $47,700.00 | 100% 0 to 30.0K | |
| 07-Jun-22 5:30 PM View: | Byrnes Michael Chief Financial Officer | Effector Therapeutics, Inc. (EFTR) | 07-Jun-22 | Private Purchase | 25,000 | $1.33 | $33,262.50 | 591% 4.23K to 29.23K | |
| 09-Jun-22 6:00 AM View: | Worland Stephen T President and Chief Executive Director | Effector Therapeutics, Inc. (EFTR) | 07-Jun-22 | Private Purchase | 20,000 | $1.37 | $27,400.00 | 3% 757.32K to 777.32K | |
| 19-May-22 6:16 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 19-May-22 | Sale | 8,574 | $1.69 | $14,489.80 | (< 1%) 4.4M to 4.39M | |
| 19-May-22 6:16 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 18-May-22 | Sale | 14,086 | $1.73 | $24,425.10 | (< 1%) 4.42M to 4.4M | |
| 19-May-22 6:16 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 17-May-22 | Sale | 11,767 | $1.75 | $20,580.80 | (< 1%) 4.43M to 4.42M | |
| 16-May-22 6:36 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 16-May-22 | Sale | 12,769 | $1.75 | $22,294.70 | (< 1%) 4.44M to 4.43M | |
| 17-May-22 8:44 PM View: | Worland Stephen T President and Chief Executive Director | Effector Therapeutics, Inc. (EFTR) | 13-May-22 | Grant | 1,837 | $1.53 | $2,810.61 | < 1% 755.48K to 757.32K | |
| 17-May-22 8:46 PM View: | Byrnes Michael Chief Financial Officer | Effector Therapeutics, Inc. (EFTR) | 13-May-22 | Grant | 4,233 | $1.53 | $6,476.49 | 100% 0 to 4.23K | |
| 16-May-22 6:36 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 13-May-22 | Sale | 22,607 | $1.84 | $41,574.30 | (< 1%) 4.46M to 4.44M | |
| 16-May-22 6:36 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 12-May-22 | Sale | 10,800 | $2.00 | $21,632.40 | (< 1%) 4.48M to 4.46M | |
| 11-May-22 8:10 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 11-May-22 | Sale | 5,000 | $2.35 | $11,725.20 | (< 1%) 4.48M to 4.48M | |
| 11-May-22 8:10 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 10-May-22 | Sale | 39,984 | $2.41 | $96,481.40 | (< 1%) 4.52M to 4.48M | |
| 11-May-22 8:10 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 09-May-22 | Sale | 4,000 | $2.54 | $10,144.10 | (< 1%) 4.52M to 4.52M | |
| 22-Feb-22 4:59 PM View: | Ehrlich Christopher B Director | Effector Therapeutics, Inc. (EFTR) | 18-Feb-22 | Purchase | 1,000 | $4.30 | $4,300.00 | < 1% 158.2K to 159.2K | |
| 22-Feb-22 4:59 PM View: | Ehrlich Christopher B Director | Effector Therapeutics, Inc. (EFTR) | 14-Feb-22 | Private Purchase | 2,000 | $4.45 | $8,900.00 | 1% 156.2K to 158.2K | |
| 10-Feb-22 5:05 PM View: | Ehrlich Christopher B Director | Effector Therapeutics, Inc. (EFTR) | 09-Feb-22 | Purchase | 1,000 | $4.75 | $4,750.00 | < 1% 155.2K to 156.2K | |
| 10-Feb-22 5:05 PM View: | Ehrlich Christopher B Director | Effector Therapeutics, Inc. (EFTR) | 08-Feb-22 | Private Purchase | 1,000 | $4.92 | $4,920.00 | < 1% 154.2K to 155.2K | |
| 07-Feb-22 9:00 AM View: | Ehrlich Christopher B Director | Effector Therapeutics, Inc. (EFTR) | 04-Feb-22 | Purchase | 1,000 | $5.00 | $5,000.00 | < 1% 153.2K to 154.2K | |
| 07-Feb-22 9:00 AM View: | Ehrlich Christopher B Director | Effector Therapeutics, Inc. (EFTR) | 03-Feb-22 | Private Purchase | 5,000 | $5.15 | $25,750.00 | 3% 148.2K to 153.2K | |
| 31-Jan-22 5:50 PM View: | Ehrlich Christopher B Director | Effector Therapeutics, Inc. (EFTR) | 27-Jan-22 | Private Purchase | 5,000 | $5.30 | $26,515.00 | 3% 143.2K to 148.2K | |
| 06-Dec-21 7:27 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 02-Dec-21 | Market Sale | 8,113 | $5.68 | $46,081.80 | (< 1%) 4.53M to 4.52M | (< 1%) |
| 06-Dec-21 7:28 PM View: | Root Jonathan D Director 10% Owner | Effector Therapeutics, Inc. (EFTR) | 02-Dec-21 | Market Sale Duplicate | 8,113 | $5.68 | $46,081.80 | (< 1%) 4.53M to 4.52M | (< 1%) |
| 01-Dec-21 6:31 PM View: | Presidio Management Group X... 10% Owner | Effector Therapeutics, Inc. (EFTR) | 01-Dec-21 | Market Sale Duplicate | 19,245 | $6.44 | $123,880.00 | (< 1%) 4.55M to 4.53M | |
| 01-Dec-21 6:31 PM View: | Root Jonathan D Director 10% Owner | Effector Therapeutics, Inc. (EFTR) | 01-Dec-21 | Market Sale | 19,245 | $6.44 | $123,880.00 | (< 1%) 4.55M to 4.53M | (2%) |
